Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$1.38
+0.7%
$1.35
$1.20
$7.13
$9.34M62.12652,361 shs64,526 shs
GBNHF
Greenbrook TMS
$0.09
-18.0%
$0.09
$0.04
$0.84
$3.71M1.881.46 million shs1,290 shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$0.22
$0.23
$0.14
$2.38
$5.42M1.27785,204 shs51,007 shs
Ontrak, Inc. stock logo
OTRK
Ontrak
$0.28
+3.7%
$0.32
$0.14
$4.08
$13.38M2.54.85 million shs347,505 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
+0.74%-3.52%+5.38%-6.80%+136,999,900.00%
GBNHF
Greenbrook TMS
0.00%+13.96%+7.57%+11,509,900.00%+11,509,900.00%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-0.05%-15.02%-10.25%-7.01%-80.96%
Ontrak, Inc. stock logo
OTRK
Ontrak
-10.20%+2.73%-39.18%+41.59%-90.09%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
2.5424 of 5 stars
0.03.00.00.03.05.01.3
GBNHF
Greenbrook TMS
N/AN/AN/AN/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Ontrak, Inc. stock logo
OTRK
Ontrak
2.9832 of 5 stars
3.55.00.00.02.60.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/A
GBNHF
Greenbrook TMS
N/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/A
Ontrak, Inc. stock logo
OTRK
Ontrak
3.00
Buy$4.001,334.21% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$150K62.28N/AN/A$2.45 per share0.56
GBNHF
Greenbrook TMS
$73.79M0.05N/AN/A($2.47) per share-0.04
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$730K7.42N/AN/A$0.04 per share5.50
Ontrak, Inc. stock logo
OTRK
Ontrak
$12.74M1.05N/AN/A$0.37 per share0.75

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$14.41M-$3.51N/AN/AN/A-9,873.97%-114.84%-107.19%N/A
GBNHF
Greenbrook TMS
-$48.91M-$2.12N/AN/A-66.21%N/A-57.65%N/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-$9.21MN/A0.00N/A-1,260.81%-411.62%-366.32%7/1/2024 (Estimated)
Ontrak, Inc. stock logo
OTRK
Ontrak
-$27.92M-$6.17N/AN/AN/A-219.10%-657.19%-126.99%8/14/2024 (Estimated)

Latest BRTX, MGRX, OTRK, and GBNHF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024Q1 2024
GBNHF
Greenbrook TMS
N/A-$0.32-$0.32-$0.32N/A$18.01 million    
5/14/2024Q1 2024
Ontrak, Inc. stock logo
OTRK
Ontrak
-$0.19-$0.11+$0.08-$0.11$2.70 million$2.68 million    
4/16/2024Q4 2023
Ontrak, Inc. stock logo
OTRK
Ontrak
N/A-$0.29-$0.29-$0.29N/A$3.54 million
4/1/2024Q4 2023
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$0.13-$0.13-$0.13N/A$0.24 million
3/29/2024Q4 2023
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/A-$0.57-$0.57-$0.57$0.03 million$0.02 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/AN/A
GBNHF
Greenbrook TMS
N/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/A
Ontrak, Inc. stock logo
OTRK
Ontrak
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/A
10.72
10.72
GBNHF
Greenbrook TMS
N/A
0.46
0.46
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A
3.88
3.79
Ontrak, Inc. stock logo
OTRK
Ontrak
0.10
3.24
3.24

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
69.38%
GBNHF
Greenbrook TMS
N/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
56.72%
Ontrak, Inc. stock logo
OTRK
Ontrak
12.95%

Insider Ownership

CompanyInsider Ownership
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
21.60%
GBNHF
Greenbrook TMS
21.67%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
46.40%
Ontrak, Inc. stock logo
OTRK
Ontrak
1.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
116.77 million5.31 millionNot Optionable
GBNHF
Greenbrook TMS
49240.80 million31.96 millionN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
324.62 million13.20 millionNot Optionable
Ontrak, Inc. stock logo
OTRK
Ontrak
10247.97 million47.39 millionNo Data

BRTX, MGRX, OTRK, and GBNHF Headlines

Recent News About These Companies

Ontrak (OTRK) to Release Quarterly Earnings on Tuesday
Ontrak, Inc. (OTRK) Q4 2023 Earnings Call Transcript
Is Ontrak stock a buy?
Ontrak Launches New Engagement System
Why Is Ontrak (OTRK) Stock Up 105% Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioRestorative Therapies logo

BioRestorative Therapies

NASDAQ:BRTX
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Greenbrook TMS

NASDAQ:GBNHF
Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services. As of December 31, 2021, the company operated 94 wholly owned and 55 TMS centers in the commonwealth of Virginia and the States of Maryland, Delaware, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, Michigan, Alaska, Oregon, California, Iowa, and Massachusetts. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.
Mangoceuticals logo

Mangoceuticals

NASDAQ:MGRX
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Ontrak logo

Ontrak

NASDAQ:OTRK
Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was incorporated in 2003 and is headquartered in Miami, Florida.